Mohammed Gbadamosi

Has grant

Assistant Professor

University of Florida

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Mohammed Gbadamosi is an Assistant Professor at the University of Florida in the United States. His research focuses on chemotherapy and immunotherapy, particularly in relation to triple-negative breast cancer and pediatric acute myeloid leukemia (AML). His recent publications include studies on DNA damage response pharmacogenomics and the efficacy of novel therapeutics in cancer treatment.

Recent Grants

Grant: Open

Decoding the Heterogeneity in Chemo-Immunomodulation to Unlock the Potential of Chemoimmunotherapy in Metastatic Triple-Negative Breast Cancer

Open Date: 2023-09-22

Close Date: 2028-07-31

Grant: Close

Pharmacogenomic Drivers of Efficacy in Anti-CD33 Immunotherapeutic Treatment Strategies

Open Date: 2020-09-01

Close Date: 2021-08-31

Articles (8)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

UNITED STATES

View details

Xueyuan Cao

Associate Professor

University of Tennessee

UNITED STATES

View details

Christopher Cogle

Professor

University of Florida College of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mohammed Gbadamosi

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (8)

DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children’s Oncology Group

Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy

Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy

A genome-wide association study using HapMap cell lines reveals modulators of cellular response to cyclophosphamide

DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children's Oncology Group.

Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML

A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.

Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms

Collaborators (7)

Todd Alonzo

Soheil Meshinchi

Jatinder Lamba

Alan Gamis

Nathan Seligson

Xueyuan Cao

Christopher Cogle

Make your next move.

Mohammed Gbadamosi

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (8)

DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children’s Oncology Group

Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy

Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy

A genome-wide association study using HapMap cell lines reveals modulators of cellular response to cyclophosphamide

DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children&#x27;s Oncology Group.

Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AML

A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.

Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms

Collaborators (7)

Todd Alonzo

Soheil Meshinchi

Jatinder Lamba

Alan Gamis

Nathan Seligson

Xueyuan Cao

Christopher Cogle

Make your next move.

DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children's Oncology Group.